Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2019 Q1- Text added to 2019 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
New words:
adjuvant, approved, assessed, atezolizumab, capecitabine, CDK, central, CNS, cohort, Committee, correlation, cycle, Data, DCR, delivered, diagnostic, disease, DoR, dual, duration, efficacy, elderly, endocrine, endpoint, enrollment, expansion, facilitate, FDA, Food, forecast, futile, futility, half, hormone, HR, IDMC, Independent, infusion, inhibitor, intravenously, IO, IRC, kinase, MBC, mg, Monitoring, monotherapy, Nasdaq, neoadjuvant, nivolumab, ORR, OS, outcome, pembrolizumab, PFS, positive, primary, Radiologic, recommended, response, Restated, Review, secondary, setting, survival, system, taxane, therapy, TNBC, treated, TRIO, underwritten
Removed:
support
Valuein 2019 Q1 filing- Value in 2019 Q2 filing
Original filings
Filing view